Literature DB >> 28513806

Increased activity of vascular adenosine deaminase in atherosclerosis and therapeutic potential of its inhibition.

Barbara Kutryb-Zajac1, Lukasz Mateuszuk2, Paulina Zukowska1, Agnieszka Jasztal2, Magdalena A Zabielska1, Marta Toczek1, Patrycja Jablonska1, Agnieszka Zakrzewska2, Barbara Sitek2, Jan Rogowski3, Romuald Lango4, Ewa M Slominska1, Stefan Chlopicki2, Ryszard T Smolenski1.   

Abstract

AIMS: Extracellular nucleotides and adenosine that are formed or degraded by membrane-bound ecto-enzymes could affect atherosclerosis by regulating the inflammation and thrombosis. This study aimed to evaluate a relation between ecto-enzymes that convert extracellular adenosine triphosphate to adenine dinucleotide phosphate, adenosine monophosphate, adenosine, and inosine on the surface of the vessel wall with the severity or progression of experimental and clinical atherosclerosis. Furthermore, we tested whether the inhibition of adenosine deaminase will block the development of experimental atherosclerosis. METHODS AND
RESULTS: Vascular activities of ecto-nucleoside triphosphate diphosphohydrolase 1, ecto-5'-nucleotidase, and ecto-adenosine deaminase (eADA) were measured in aortas of apolipoprotein E-/- low density lipoprotein receptor (ApoE-/-LDLR-/-) and wild-type mice as well as in human aortas. Plaques were analysed in the entire aorta, aortic root, and brachiocephalic artery by Oil-Red O and Orcein Martius Scarlet Blue staining and vascular accumulation of macrophages. The cellular location of ecto-enzymes was analysed by immunofluorescence. The effect of eADA inhibition on atherosclerosis progression was studied by a 2-month deoxycoformycin treatment of ApoE-/-LDLR-/- mice. The vascular eADA activity prominently increased in ApoE-/-LDLR-/- mice when compared with wild type already at the age of 1 month and progressed along atherosclerosis development, reaching a 10-fold difference at 10 months. The activity of eADA correlated with atherosclerotic changes in human aortas. High abundance of eADA in atherosclerotic vessels originated from activated endothelial cells and macrophages. There were no changes in ecto-nucleoside triphosphate diphosphohydrolase 1 activity, whereas ecto-5'-nucleotidase was moderately decreased in ApoE-/-LDLR-/- mice. Deoxycoformycin treatment attenuated plaque development in aortic root and brachiocephalic artery of ApoE-/-LDLR-/- mice, suppressed vascular inflammation and improved endothelial function.
CONCLUSIONS: This study highlights the importance of extracellular nucleotides and adenosine metabolism in the atherosclerotic vessel in both experimental and clinical setting. The increased eADA activity marks an early stage of atherosclerosis, contributes to its progression and could represent a novel target for therapy. Published on behalf of the European Society of Cardiology. All rights reserved.
© The Author 2016. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  Adenosine; Adenosine deaminase; Atherosclerosis; Endothelium; Nucleotides

Mesh:

Substances:

Year:  2016        PMID: 28513806     DOI: 10.1093/cvr/cvw203

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN: 0008-6363            Impact factor:   10.787


  14 in total

1.  Differences in Extracellular NAD+ and NMN Metabolism on the Surface of Vascular Endothelial Cells.

Authors:  Patrycja Jablonska; Paulina Mierzejewska; Marta Tomczyk; Patrycja Koszalka; Marika Franczak; Ada Kawecka; Barbara Kutryb-Zajac; Alicja Braczko; Ryszard T Smolenski; Ewa M Slominska
Journal:  Biology (Basel)       Date:  2022-04-27

2.  Identification of Adenosine Deaminase Inhibitors by Metal-binding Pharmacophore Screening.

Authors:  Rebecca N Adamek; Paul Ludford; Stephanie M Duggan; Yitzhak Tor; Seth M Cohen
Journal:  ChemMedChem       Date:  2020-10-14       Impact factor: 3.466

3.  Molecular Evidence of Adenosine Deaminase Linking Adenosine A2A Receptor and CD26 Proteins.

Authors:  Estefanía Moreno; Júlia Canet; Eduard Gracia; Carme Lluís; Josefa Mallol; Enric I Canela; Antoni Cortés; Vicent Casadó
Journal:  Front Pharmacol       Date:  2018-02-15       Impact factor: 5.810

4.  Nucleotide ecto-enzyme metabolic pattern and spatial distribution in calcific aortic valve disease; its relation to pathological changes and clinical presentation.

Authors:  Barbara Kutryb-Zajac; Patrycja Jablonska; Marcin Serocki; Alicja Bulinska; Paulina Mierzejewska; Daniela Friebe; Christina Alter; Agnieszka Jasztal; Romuald Lango; Jan Rogowski; Rafal Bartoszewski; Ewa M Slominska; Stefan Chlopicki; Jürgen Schrader; Magdi H Yacoub; Ryszard T Smolenski
Journal:  Clin Res Cardiol       Date:  2019-05-29       Impact factor: 5.460

5.  Baseline serum triglyceride predicts early-onset peritonitis and prognosis in incident CAPD patients.

Authors:  Sheng Wan; Hongdan Tian; Li Cheng; Yanqiong Ding; Qing Luo; Yanmin Zhang
Journal:  Medicine (Baltimore)       Date:  2021-01-15       Impact factor: 1.817

6.  An unusual nicotinamide derivative, 4-pyridone-3-carboxamide ribonucleoside (4PYR), is a novel endothelial toxin and oncometabolite.

Authors:  Paulina Mierzejewska; Michal Kunc; Magdalena Agnieszka Zabielska-Kaczorowska; Barbara Kutryb-Zajac; Iwona Pelikant-Malecka; Alicja Braczko; Patrycja Jablonska; Pawel Romaszko; Patrycja Koszalka; Jolanta Szade; Ryszard Tomasz Smolenski; Ewa Maria Slominska
Journal:  Exp Mol Med       Date:  2021-09-27       Impact factor: 12.153

7.  The new insight into extracellular NAD+ degradation-the contribution of CD38 and CD73 in calcific aortic valve disease.

Authors:  Patrycja Jablonska; Barbara Kutryb-Zajac; Paulina Mierzejewska; Agnieszka Jasztal; Barbara Bocian; Romuald Lango; Jan Rogowski; Stefan Chlopicki; Ryszard T Smolenski; Ewa M Slominska
Journal:  J Cell Mol Med       Date:  2021-06-18       Impact factor: 5.310

8.  Adenosine deaminase inhibition suppresses progression of 4T1 murine breast cancer by adenosine receptor-dependent mechanisms.

Authors:  Barbara Kutryb-Zajac; Patrycja Koszalka; Paulina Mierzejewska; Alicja Bulinska; Magdalena A Zabielska; Karolina Brodzik; Aleksandra Skrzypkowska; Lukasz Zelazek; Iwona Pelikant-Malecka; Ewa M Slominska; Ryszard T Smolenski
Journal:  J Cell Mol Med       Date:  2018-10-05       Impact factor: 5.310

9.  Evaluation of Plasma Adenosine as a Marker of Cardiovascular Risk: Analytical and Biological Considerations.

Authors:  Trevor Simard; Richard Jung; Alisha Labinaz; Mohammad Ali Faraz; F Daniel Ramirez; Pietro Di Santo; Dylan Perry-Nguyen; Ian Pitcher; Pouya Motazedian; Chantal Gaudet; Rebecca Rochman; Jeffrey Marbach; Paul Boland; Kiran Sarathy; Saleh Alghofaili; Juan J Russo; Etienne Couture; Steven Promislow; Rob S Beanlands; Benjamin Hibbert
Journal:  J Am Heart Assoc       Date:  2019-08-05       Impact factor: 5.501

Review 10.  Therapeutic Perspectives of Adenosine Deaminase Inhibition in Cardiovascular Diseases.

Authors:  Barbara Kutryb-Zajac; Paulina Mierzejewska; Ewa M Slominska; Ryszard T Smolenski
Journal:  Molecules       Date:  2020-10-12       Impact factor: 4.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.